These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37637431)

  • 41. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
    Kong W; Yang X; Shu Y; Li S; Song B; Yang K
    Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
    Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
    Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study.
    Chen Y; Luo J; Chen J; Kotlyar E; Li Z; Chen W; Li J
    Front Pharmacol; 2021; 12():811700. PubMed ID: 35095523
    [No Abstract]   [Full Text] [Related]  

  • 47. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
    Xu X; Fang N; Li H; Liu Y; Yang F; Li X
    Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study).
    Tamura Y; Kumamaru H; Tsujino I; Suda R; Abe K; Inami T; Horimoto K; Adachi S; Yasuda S; Sera F; Taniguchi Y; Kuwana M; Tatsumi K;
    Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
    Jain S; Khera R; Girotra S; Badesch D; Wang Z; Murad MH; Blevins A; Schmidt GA; Singh S; Gerke AK
    Chest; 2017 Jan; 151(1):90-105. PubMed ID: 27615023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.
    Kaplan RI; De Moraes CG; Cioffi GA; Al-Aswad LA; Blumberg DM
    JAMA Ophthalmol; 2015 May; 133(5):560-7. PubMed ID: 25741886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.
    Chen M; Lai Y; Chen R; Lu J; Zhang Y; Liu H; Wang D; Zhong Y; Zheng Z; Hong C
    Pulm Pharmacol Ther; 2022 Feb; 72():102100. PubMed ID: 34856365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacotherapy for pulmonary arterial hypertension.
    Parikh V; Bhardwaj A; Nair A
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1767-S1781. PubMed ID: 31632754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
    Zhou Y; Long E; Xu Q; Wang L; Jiang X; Hu M
    Front Public Health; 2021; 9():713258. PubMed ID: 34395374
    [No Abstract]   [Full Text] [Related]  

  • 57. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 60. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.